Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Stocktwits on MSN2d
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MT Newswires on MSN2h
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late Thursday morning, declining 0.04% to 1,402.70 on the S&P Europe Select ADR Index. From continental ...
Nasdaq3d
Biodexa Pharmaceuticals Receives FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
Yahoo Finance6d
Biodexa Pharmaceuticals Plc (BDRX)
Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for ...